MARKET

CLYM

CLYM

Climb Bio
NASDAQ
7.03
-0.23
-3.17%
After Hours: 6.83 -0.2 -2.85% 16:53 03/13 EDT
OPEN
7.29
PREV CLOSE
7.26
HIGH
7.45
LOW
6.83
VOLUME
446.01K
TURNOVER
--
52 WEEK HIGH
8.04
52 WEEK LOW
1.050
MARKET CAP
335.81M
P/E (TTM)
-7.9651
1D
5D
1M
3M
1Y
5Y
1D
Analysts’ Top Healthcare Picks: Climb Bio (CLYM), Nektar Therapeutics (NKTR)
TipRanks · 1d ago
CLIMB BIO INC <CLYM.O>: RAYMOND JAMES INITIATES COVERAGE WITH STRONG BUY RATING; TARGET PRICE $25
Reuters · 2d ago
Climb Bio Price Target Announced at $25.00/Share by Raymond James
Dow Jones · 2d ago
Climb Bio Initiated at Strong Buy by Raymond James
Dow Jones · 2d ago
Climb Bio initiated with a Strong Buy at Raymond James
TipRanks · 3d ago
Climb Bio Price Target Raised to $15.00/Share From $11.00 by HC Wainwright & Co.
Dow Jones · 3d ago
Climb Bio Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 3d ago
HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $15
Benzinga · 3d ago
More
About CLYM
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).

Webull offers Climb Bio Inc stock information, including NASDAQ: CLYM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLYM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLYM stock methods without spending real money on the virtual paper trading platform.